Observation for the curative effect of Xiakucao oral liquid on hashimoto thyroiditis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027884

Enrollment

Unknown

Registered

2019-12-02

Start date

2018-10-08

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hashimoto's thyroiditis

Interventions

Group A:Xiakucao oral liquid

Group B:placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years; 2. thyroid anti-peroxidase antibody (tpo-ab) > 300 (IU/ml); 3. Ultrasonic examination of the thyroid showed goiter with uneven echo, which may be accompanied by multiple hypoechoic regions or thyroid nodules; 4. normal thyroid function (including normal thyroid function after taking LT4); 5. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. febrile, pregnant or nursing women; 2. Severe dysfunction of heart, liver and kidney and other autoimmune diseases; 3. thyroid cancer patients and thyroid dysfunction caused by other reasons; 4. Take other drugs that interfere with thyroid function within the past month; 5. Patients allergic to test drugs.

Design outcomes

Primary

Measure	Time frame
Thyroid peroxidase antibody;antithyroglobulin antibody;thyrotropin;Free thyroxine;	—

Secondary

Measure	Time frame
Urine iodine content;Thyroid ultrasound;Liver function;Kidney function;Blood routine;Urine routine;Stool Routine;	—

Contacts

Public ContactZhongyan Shan

1st Affiliated Hospital of China Medical University

shanzhongyan@medmail.com.cn+86 138 0490 5018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026